ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005


The Latest on X

Kidney Week

Please note that you are viewing an archived section from 2023 and some content may be unavailable. To unlock all content for 2023, please visit the archives.

Abstract: TH-OR98

Canagliflozin Pharmacokinetics at Steady State in Patients on Maintenance Hemodialysis

Session Information

Category: Pharmacology (PharmacoKinetics, -Dynamics, -Genomics)

  • 2000 Pharmacology (PharmacoKinetics, -Dynamics, -Genomics)


  • Mavrakanas, Thomas, McGill University Health Centre, Montreal, Quebec, Canada
  • Gritsas, Ari, McGill University Health Centre, Montreal, Quebec, Canada
  • Tsirella, Efrosyne, McGill University Health Centre, Montreal, Quebec, Canada
  • Rios, Norka, McGill University Health Centre, Montreal, Quebec, Canada
  • Sharma, Abhinav, McGill University Health Centre, Montreal, Quebec, Canada
  • Suri, Rita, McGill University Health Centre, Montreal, Quebec, Canada

Sodium glucose co-transporter 2 (SGLT-2) inhibitors improve cardiovascular and kidney outcomes in patients with preserved renal function or with mild and moderate chronic kidney disease. However, they have not been studied in patients on maintenance hemodialysis (HD). Detailed study of SGLT-2 inhibitor pharmacokinetics in patients receiving HD is the first step to establishing their safety in this population.


Patients with kidney failure on maintenance HD for at least 3 months were invited to participate. Those with type 1 diabetes mellitus, euglycemic ketoacidosis, or liver disease were excluded. All participants received 100 mg of canagliflozin once daily for nine days. Venous blood samples were collected immediately before (0) and 1, 1.5, 2, 3, 4, 6, 9, 12, and 24 hours after canagliflozin administration for pharmacokinetic analyses on day 8 (a mid-week non-dialysis day) and hourly during hemodialysis on day 9. Canagliflozin plasma levels were measured with liquid chromatography- mass spectrometry and compared to published estimates in healthy controls.


We enrolled 10 patients (59 ± 14 years old, 30% female, median dialysis duration 26 months). Canagliflozin levels reached steady state on day 4, based on a calculated half-life of 7.3 hours. Pharmacokinetic results on day 8 are shown in the Table. There were no significant differences in drug exposure, peak plasma levels, nor time to peak plasma levels between our patients and patients with preserved renal function. Canagliflozin levels were not modified by hemodialysis (p=0.39).


Drug exposure with canagliflozin 100 mg daily is similar between patients receiving HD and individuals with preserved kidney function, and levels were not affected by HD. These results suggest canagliflozin does not accumulate in HD patients and trials of canagliflozin may be safely conducted in patients on HD to test its efficacy.

Canagliflozin pharmacokinetics in hemodialysis
ParameterHemodialysisPreserved renal functionp-value
AUC0-24 (ng.h/ml)8267 ± 42656377 ± 12850.19
Cmin (ng/ml)87 (57-201)--
tmax (hours)2.1 (1.9-3.2)2.0 (1.0-4.0)0.18
Cmax (ng/ml)1122 ± 537943 ± 2390.32

AUC0-24, drug exposure (area under the curve between 0 and 24h); Cmin, trough level; tmax, time to peak plasma concentration; Cmax, peak plasma concentration.


  • Private Foundation Support